What is GAMMAGARD LIQUID?
Immune globulin (IG) for patients with primary immunodeficiency (PI), adults with multifocal motor neuropathy (MMN), or adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
GAMMAGARD LIQUID is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older, as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN), and as a therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
LIMITATIONS OF USE (CIDP): GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP. GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with GAMMAGARD LIQUID in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient’s response and demonstrated need for continued therapy.
GAMMAGARD LIQUID for PI is for intravenous or subcutaneous use.
GAMMAGARD LIQUID for MMN and CIDP is for intravenous use only.
GAMMAGARD LIQUID is the most utilized IG in the US for 15 years2 (based on 2005-2019 aggregate analysis)
FDA-approved for PI 2005; FDA-approved for MMN [2012]As a leading IG, GAMMAGARD LIQUID is a trusted therapy with more than 15 years of clinical use.2-5
Supported by a legacy of leadership
GAMMAGARD LIQUID is built on more than 60 years of global heritage in IG therapies.6 See how our history translates into world-class manufacturing standards today—and how we’re actively preparing to serve patients tomorrow.
See our commitment
Formulated with patient needs in mind1
Not all intravenous immune globulin (IVIG) formulations are interchangeable.7-9 GAMMAGARD LIQUID is formulated to help you meet the needs of many patient types, including those with specific conditions and risk factors.1,10 Watch an overview of how GAMMAGARD LIQUID is made and explore product characteristics.
See product characteristics
Established safety profile
GAMMAGARD LIQUID has an established safety and tolerability profile.1 Explore safety information to consider when initiating and monitoring treatment with GAMMAGARD LIQUID.
Review safety information
Designed for ease of use
GAMMAGARD LIQUID is offered in a broad range of vial sizes, potentially minimizing product waste.1 Explore information on vial sizes, shelf life, and storage requirements.
See vial size and storage